GSA Capital Partners’s Puma Biotechnology PBYI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-99,394
| Closed | -$294K | – | 2051 |
|
|
2025
Q1 | $294K | Sell |
99,394
-9,129
| -8% | -$28.6K | 0.03% | 1172 |
|
|
2024
Q4 | $331K | Buy |
108,523
+59,029
| +119% | +$172K | 0.02% | 1152 |
|
|
2024
Q3 | $126K | Sell |
49,494
-140,257
| -74% | -$425K | 0.01% | 1470 |
|
|
2024
Q2 | $619K | Buy |
189,751
+2,166
| +1% | +$9.51K | 0.04% | 829 |
|
|
2024
Q1 | $994K | Sell |
187,585
-74,752
| -28% | -$403K | 0.08% | 441 |
|
|
2023
Q4 | $1.14M | Sell |
262,337
-17,292
| -6% | -$57.3K | 0.1% | 332 |
|
|
2023
Q3 | $735K | Buy |
279,629
+164,931
| +144% | +$562K | 0.06% | 565 |
|
|
2023
Q2 | $405K | Buy |
+114,698
| New | +$358K | 0.04% | 870 |
|
|
2023
Q1 | – | Sell |
-72,940
| Closed | -$309K | – | 1824 |
|
|
2022
Q4 | $309K | Sell |
72,940
-67,381
| -48% | -$233K | 0.04% | 914 |
|
|
2022
Q3 | $333K | Buy |
140,321
+71,572
| +104% | +$209K | 0.04% | 857 |
|
|
2022
Q2 | $196K | Sell |
68,749
-70,194
| -51% | -$175K | 0.03% | 1076 |
|
|
2022
Q1 | $400K | Buy |
+138,943
| New | +$359K | 0.05% | 700 |
|
|
2021
Q4 | – | Sell |
-86,040
| Closed | -$603K | – | 1693 |
|
|
2021
Q3 | $603K | Buy |
86,040
+71,155
| +478% | +$533K | 0.06% | 588 |
|
|
2021
Q2 | $137K | Buy |
+14,885
| New | +$151K | 0.02% | 1226 |
|
|
2020
Q1 | – | Sell |
-83,686
| Closed | -$732K | – | 1426 |
|
|
2019
Q4 | $732K | Buy |
83,686
+59,186
| +242% | +$490K | 0.09% | 392 |
|
|
2019
Q3 | $264K | Sell |
24,500
-5,218
| -18% | -$56.3K | 0.04% | 1013 |
|
|
2019
Q2 | $378K | Buy |
29,718
+23,283
| +362% | +$536K | 0.04% | 843 |
|
|
2019
Q1 | $250K | Buy |
+6,435
| New | +$197K | 0.03% | 1109 |
|
|
2015
Q3 | – | Sell |
-34,625
| Closed | -$4.04M | – | 1964 |
|
|
2015
Q2 | $4.04M | Buy |
34,625
+23,511
| +212% | +$4.26M | 0.16% | 86 |
|
|
2015
Q1 | $2.62M | Buy |
11,114
+6,521
| +142% | +$1.39M | 0.1% | 209 |
|
|
2014
Q4 | $869K | Sell |
4,593
-3,506
| -43% | -$778K | 0.06% | 563 |
|
|
2014
Q3 | $1.93M | Buy |
+8,099
| New | +$1.66M | 0.1% | 204 |
|
|
2014
Q2 | – | Sell |
-15,698
| Closed | -$1.64M | – | 1924 |
|
|
2014
Q1 | $1.64M | Buy |
+15,698
| New | +$1.85M | 0.12% | 168 |
|
|
2013
Q4 | – | Sell |
-11,500
| Closed | -$617K | – | 1740 |
|
|
2013
Q3 | $617K | Buy |
11,500
+2,900
| +34% | +$156K | 0.05% | 640 |
|
|
2013
Q2 | $382K | Buy |
+8,600
| New | +$303K | 0.05% | 725 |
|
Other funds holding PBYI
ACA
KCM
GSA Capital Partners's PBYI Position: Q2 2025 in Review
GSA Capital Partners sold out of Puma Biotechnology (PBYI) in Q2 2025, closing a stake of 99,394 shares — an estimated $294K sold.
GSA Capital Partners first reported a position in PBYI in Q2 2013 and held it in 25 quarters. The position peaked at $4.04M in Q2 2015. 121 funds tracked by Wall St. Rank hold PBYI as of Q2 2025.
- GSA Capital Partners reported no remaining Puma Biotechnology position as of Q2 2025 after selling out during the quarter.
- GSA Capital Partners sold 99,394 Puma Biotechnology shares in Q2 2025, an estimated $294K.
- GSA Capital Partners first reported a position in Puma Biotechnology in Q2 2013 and held it in 25 quarters.
- GSA Capital Partners's Puma Biotechnology position peaked at $4.04M in Q2 2015.
- 121 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2025.
Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.